To test whether treatment with low molecular weight heparin (LMWH) is superior to aspirin for the prevention of recurrent stroke during the first 14 days.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dalteparin (Fragmin®)Drug
Other Names: Fragmin Intervention Desc: Low molecular weight heparin
- LMW heparin Drug
Intervention Desc: Low molecular weight heparin and heparinoids. See also specific compounds, including danaparoid, dalteparin, enoxaparin, nadroparin, tinzaparin.
Multicenter, randomized, double-blind, and dummy-controlled trial of 449 patients.
Patients were randomized to receive dalteparin 100 IU/kg subcutaneously twice a day) and placebo or aspirin (160 mg every day).
|Type||Measure||Time Frame||Safety Issue|
|Primary||Ischemic stroke recurrence during first 14 days of treatment.|
|Secondary||Symptomatic cerebral hemorrhage, symptomatic and asymptomatic cerebral hemorrhage, progression of symptoms within first 48 hours, death and functional outcome.|